IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

MORA, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.076
EU - Europa 1.177
AS - Asia 1.026
Continente sconosciuto - Info sul continente non disponibili 101
SA - Sud America 98
AF - Africa 18
OC - Oceania 2
Totale 5.498
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.011
IT - Italia 559
SG - Singapore 382
CN - Cina 184
VN - Vietnam 159
UA - Ucraina 137
HK - Hong Kong 111
SE - Svezia 105
TR - Turchia 93
BR - Brasile 80
GB - Regno Unito 70
IE - Irlanda 67
DE - Germania 66
FR - Francia 43
CA - Canada 36
BD - Bangladesh 35
FI - Finlandia 32
RU - Federazione Russa 31
IN - India 17
JP - Giappone 16
MX - Messico 12
PL - Polonia 12
CZ - Repubblica Ceca 10
NL - Olanda 10
ZA - Sudafrica 10
ES - Italia 8
AR - Argentina 7
LT - Lituania 6
PK - Pakistan 6
BE - Belgio 5
AT - Austria 4
CL - Cile 4
HN - Honduras 4
KE - Kenya 4
CR - Costa Rica 3
MD - Moldavia 3
PR - Porto Rico 3
SA - Arabia Saudita 3
TH - Thailandia 3
UZ - Uzbekistan 3
VE - Venezuela 3
EC - Ecuador 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
IQ - Iraq 2
KR - Corea 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EU - Europa 1
ID - Indonesia 1
JM - Giamaica 1
LB - Libano 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.398
Salva come PNG Salva come JPEG
Città #
Milan 378
Fairfield 323
Ashburn 272
Woodbridge 226
San Jose 213
Singapore 208
Houston 165
Seattle 151
Chandler 150
Jacksonville 121
Wilmington 121
Cambridge 117
Ann Arbor 113
Hong Kong 106
Nyköping 77
Council Bluffs 73
Dallas 72
Princeton 65
Dublin 64
Izmir 48
The Dalles 44
Beijing 43
Boardman 43
Dearborn 38
Lauterbourg 34
Dong Ket 33
San Diego 32
Los Angeles 29
Hanoi 27
Santa Clara 26
Ho Chi Minh City 25
New York 25
Rome 25
Como 22
London 22
Ogden 20
Helsinki 18
Redmond 18
Orem 16
Chicago 14
Toronto 14
Kocaeli 13
Munich 13
São Paulo 13
Tokyo 12
Atlanta 11
Brooklyn 11
Warsaw 11
Brno 9
Johannesburg 9
Mexico City 9
Phoenix 9
Washington 9
Frankfurt am Main 8
Poplar 8
San Francisco 8
Amsterdam 7
Denver 7
Montreal 7
Varese 7
Chennai 6
Columbus 6
Manchester 6
Shanghai 6
Ankara 5
Brussels 5
Dhaka 5
Guangzhou 5
Haiphong 5
Hefei 5
Miami 5
Rio de Janeiro 5
City of London 4
Da Nang 4
Falkenstein 4
Ha Long 4
Hangzhou 4
Jackson 4
Kilburn 4
Kunming 4
Nairobi 4
Ottawa 4
Redwood City 4
Boston 3
Cavaria con Premezzo 3
Charlotte 3
Concord 3
Gavirate 3
Islamabad 3
Mumbai 3
Nanchang 3
Nanjing 3
Norwalk 3
Nuremberg 3
Salt Lake City 3
Stockholm 3
Tashkent 3
Zhengzhou 3
Alvorada 2
Astana 2
Totale 3.969
Salva come PNG Salva come JPEG
Nome #
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 268
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts 255
Looking for CALR mutations in familial myeloproliferative neoplasms 229
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 227
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 225
It is time to change thrombosis risk assessment for PV and ET? 210
Developments in diagnosis and treatment of essential thrombocythemia 206
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 204
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 204
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients 201
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis 183
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 178
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms 177
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 155
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 154
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia 151
Prognostication in myelofi-brosis 148
Therapy of polycythemia vera: Is it time to change? 143
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 138
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 133
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 127
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 127
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 126
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma 126
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 126
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 121
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 120
Is there a gender effect in polycythemia vera? 113
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 108
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 105
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 101
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence 92
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 86
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 81
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 80
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 70
Totale 5.498
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022263 0 0 0 15 11 22 16 21 26 87 19 46
2022/2023473 33 13 75 43 36 102 2 56 75 13 9 16
2023/2024618 91 94 92 115 133 40 7 4 25 2 5 10
2024/2025555 15 3 79 43 23 25 18 54 84 49 42 120
2025/20261.305 106 87 70 229 132 83 245 71 129 82 54 17
2026/2027353 37 75 147 94 0 0 0 0 0 0 0 0
Totale 5.498